Beyond the Pharmacy Claim: How Employers Can Evaluate the Broader Impact of GLP-1 Programs

What People are asking Series:

This blog is part of What People Are Asking, a series inspired by recurring questions and discussions across Reddit, Quora, LinkedIn, employer forums, and conversations among HR and benefits professionals. Each article explores a real question using current research and publicly available evidence.

Beyond the Pharmacy Claim: How Employers Can Evaluate the Broader Impact of GLP-1 Programs 

Every month, the pharmacy invoice arrives on time. GLP-1 claims are itemized, dated, and impossible to miss. The medical claims that may be shifting in response, fewer emergency visits tied to diabetic complications, a lower A1c a year from now, one less cardiology referral, do not arrive with the same clarity. They surface later, spread across a different report, often under a different vendor's name That timing gap explains a lot about why pharmacy cost, rather than overall health outcomes, tends to dominate the conversation.

The bill you can see, and the one you can't

In conversations with benefits leaders, this disconnect comes up constantly. One decision-maker described watching pharmacy claims for GLP-1s climb sharply in the same period that diabetes and obesity related medical claims were trending down. Both things were happening in the same population, at the same time. Only one of them showed up as a clean number that finance could point to at the next budget review.

The visibility gap is not just a perception problem. Pharmacy spend has become genuinely hard to ignore. GLP-1s now account for roughly 11 percent of annual pharmacy claims across many employer plans, up from under 7 percent just three years earlier, according to CNBC. 

Simulation modeling from the Employee Benefit Research Institute suggests that expanding GLP-1 coverage broadly could push employer health premiums up by approximately 5 to 14 percent under the scenarios modeled, depending on factors including eligibility, adherence, and cost sharing. It is no surprise that Mercer's 2026 benchmarking survey found that 77 percent of large employers call managing GLP-1 costs extremely or very important.

‍

Are medical and pharmacy budgets evaluated together?

Usually not, and that is a structural issue rather than an oversight. Pharmacy benefits are typically carved out to a pharmacy benefit manager, while medical claims sit with a separate carrier or third-party administrator. Each comes with its own reporting cadence, its own dashboard, and its own account team. A benefits leader can be extremely well informed about pharmacy trends and still have no timely, unified view into whether that spend is buying anything back on the medical side.

This gap is not lost on employers themselves. More than half of employers covering GLP-1s for weight management expect meaningful clinical benefit, but few report seeing that benefit reflected in their own aggregated claims data, according to HFMA. The expectation of impact and the ability to measure it are two different things, and most plans today are better equipped to do the former.

What tends to get left out entirely

Beyond the medical versus pharmacy split, a few categories of impact are the most likely to go unmeasured.

• Reductions in other medications. Lower doses or discontinued use of insulin, blood pressure medication, or cholesterol drugs are a real cost offset, but they rarely get pulled into the GLP-1 conversation as their own line item.
• Avoided utilization. Fewer hospitalizations and fewer complications fall into the classic "cost avoided" category, and cost avoided is inherently harder to report than cost incurred. In an observational analysis of real-world claims data covering more than 192,000 GLP-1 users, Aon found that diabetes patients using GLP-1s experienced a six-percentage-point improvement in medical spend growth compared with matched non-users, increasing to nine percentage points among users with at least 80 percent adherence, between 12 and 30 months after initiation. For weight-loss users, Aon observed a three-percentage-point improvement between 12 and 18 months, increasing to seven percentage points among users with at least 80 percent adherence, compared with matched non-users. Because this is population-level claims data rather than a controlled trial, results reflect an association rather than a guarantee, and individual employer results will vary based on plan design and population health.
• Productivity and absenteeism. Most employers do not have a clean, ongoing way to connect a chronic condition program to fewer sick days or less presenteeism, in part because that data usually lives in an entirely separate HR system. Industry estimates put the average loss at $2,945 per employee per year in absenteeism and presenteeism tied to chronic illness, according to Marathon Health, a figure that is not specific to GLP-1 treatment but illustrates why workforce measures may be relevant when evaluating overall impact.

The time horizon problem

Even when medical offsets are measured, they often arrive on the wrong clock. The Aon findings above describe a real but gradual curve, not an immediate rebate. One case study from AssuredPartners found that GLP-1 users saved about $560 per person per year in medical costs against an average annual drug cost of $6,540, meaning the near-term math was negative for most employers, as detailed by NIS Benefits. A model that only looks at plan year one may capture pharmacy costs before longer-term medical trends have fully emerged. A model that looks across a longer period can provide a more complete view. The gap between those two views is where longer-term changes in costs and outcomes may be missed.

‍

What a fuller evaluation looks like

Employers who want to see past the pharmacy claim tend to build a few habits into how they evaluate these programs.

1. Ask for combined reporting, not two separate reports. Push the pharmacy benefit manager and the medical carrier, or a platform built to sit across both, to report on the same population over the same time period.
2. Track clinical markers alongside spend. A1c, blood pressure, weight, and comorbid claims tend to move before the medical trend line catches up, so they work as useful early signals rather than an afterthought.
3. Extend the evaluation window on purpose. Set expectations at 18, 24, and 36 months instead of judging the program at the next renewal alone.
4. Bring HR into the data conversation. Absenteeism and disability data usually sits with HR rather than the team evaluating the pharmacy line, and connecting those two datasets, even informally, closes a real gap.
5. Treat medication reduction as its own metric. If a GLP-1 program is helping employees come off other chronic medications, that is a number worth pulling and reporting on its own terms.

The pharmacy claim is one page of a longer report

The pharmacy invoice will always be the easiest number to find. It is dated, itemized, and lands in the same inbox every month. The rest of the story, the avoided complications, the medications no longer needed, the days not missed, takes real effort to assemble, because the systems involved were never built to do that work automatically.

That is the real answer to why employers focus where they do. It is not that outcomes don't count. It is that someone must go looking for them on purpose, and most financial models were never designed to do that on their own.

_Disclaimer

_{This blog is maintained by eMed for informational purposes only. Content published here does not constitute medical, legal, financial, or benefits advice and should not be relied upon as such. Third-party statistics, studies, and research cited are sourced from publicly available data and provided for general informational context only; eMed makes no representation as to their accuracy, completeness, or applicability to any specific employer population, and results may vary. eMed's Population Health GLP-1 Program for Employers pairs FDA-approved, on-label medications with clinical oversight; individual health outcomes depend on a variety of clinical and personal factors and cannot be guaranteed.}

_{Any content authored or posted by eMed employees reflects their personal opinions and perspectives only and does not represent the views, positions, or official statements of eMed or its affiliates.}